Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Pear Therapeutics, SoftBank Team On Sleep/Wake Disorder Therapeutic For Japanese Market

  • Pear Therapeutics Inc (NASDAQ:PEAR) has agreed with SoftBank Group Corp (OTC:SFTBY) to develop a Japanese-language digital therapeutic for sleep/wake disorders for the Japanese market.
  • In the U.S., Pear is marketing Somryst, the only FDA-authorized prescription digital therapeutics for treating chronic insomnia. 
  • This strategic initiative is a part of Pear's strategy to commercialize digital therapeutics in international markets. 
  • Related: Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months.
  • Under the agreement, Pear will develop digital therapeutic applications for sleep/wake disorders for the Japanese market, and SoftBank will investigate the Japanese market potential for those applications.
  • SoftBank has an option to negotiate an exclusive license for Pear's digital therapeutics for sleep/wake disorders in Japan.
  • Read Why BTIG Sees An Upside OF 55% In Pear Therapeutics.
  • Price Action: PEAR shares are up 6.76% at $4.74 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.